Premium
Antibody–drug conjugates: an emerging modality for the treatment of cancer
Author(s) -
Leal Mauricio,
Sapra Puja,
Hurvitz Sara A.,
Senter Peter,
Wahl Alan,
Schutten Melissa,
Shah Dhaval K.,
HaddishBerhane Nahor,
Kabbarah Omar
Publication year - 2014
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12499
Subject(s) - antibody drug conjugate , drug , antibody , conjugate , cytotoxic t cell , medicine , cancer , potency , payload (computing) , pharmacology , therapeutic index , monoclonal antibody , cancer research , chemistry , immunology , in vitro , computer science , biochemistry , mathematical analysis , computer network , mathematics , network packet
Antibody–drug conjugates (ADCs) offer promise as a therapeutic modality that can potentially reduce the toxicities and poor therapeutic indices caused by the lack of specificity of conventional anticancer therapies. ADCs combine the potency of cytotoxic agents with the target selectivity of antibodies by chemically linking a cytotoxic payload to an antibody, potentially creating a synthetic molecule that will deliver targeted antitumor therapy that is both safe and efficacious. The ADC repertoire contains a range of payload molecules, antibodies, and linkers. Two ADC molecules, Kadcyla® and Adcetris®, have been approved by the FDA, and many more are currently in clinical development.